58142-49-7

Basic information

• Product Name: 5-Isoquinolinamine,3-chloro-(9CI)
• Synonyms: 5-Isoquinolinamine,3-chloro-(9CI);3-CHLOROISOQUINOLIN-5-AMINE;3-Chloro-5-isoquinolinamine;5-Amino-3-chloroisoquinoline;3-Chloro-5-aminoisoquinoline;5-Isoquinolinamine, 3-chloro-;5-Amino-3-chloroisoquinoline hydrochloride
• CAS NO: 58142-49-7
• Molecular Formula: C₉H₇ClN₂
• Molecular Weight: 178.62
• Product Categories: ISOQUINOLINE
• Mol File: 58142-49-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 372.583 °C at 760 mmHg
• Flash Point: 179.132 °C
• Appearance: /
• Density: 1.363 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.14±0.43(Predicted)
• CAS DataBase Reference: 5-Isoquinolinamine,3-chloro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoquinolinamine,3-chloro-(9CI)(58142-49-7)
• EPA Substance Registry System: 5-Isoquinolinamine,3-chloro-(9CI)(58142-49-7)

Safety Data

• Hazardous Substances Data: 58142-49-7(Hazardous Substances Data)

Usage

General Description

5-Isoquinolinamine, 3-chloro-(9CI) is a chemical compound with the molecular formula C9H7ClN2. It belongs to the class of isoquinolinamine compounds and contains a chloro group attached to the third carbon atom of the isoquinolinamine ring. 5-Isoquinolinamine,3-chloro-(9CI) may have potential pharmaceutical or industrial applications due to its structural properties and reactivity. However, further research and testing are necessary to fully understand its potential uses and effects. Additionally, it is important to handle this compound with caution, as with any chemical, due to potential hazards and risks associated with its use.

Upstream product

• 824-72-6 P,P-dichlorophenylphosphine oxide 
• 89-51-0 Homophthalic acid 
• 10296-47-6 3-chloro-5-nitro-isoquinoline 
• 4456-77-3 4H-isoquinolin-1,3-dione 
• 7742-73-6 1,3-dichloroisoquinoline 
• 19493-45-9 3-chloroisoquinoline 

Downstream Products

• 581811-29-2 N-benzyl-N'-(3-chloro-5-isoquinolinyl)urea 
• 1010103-56-6 2-[(E)-2-(4-morpholin-4-ylmethylphenyl)vinyl]-9,10,11,12-tetrahydro-8H-3,8,12-triaza-naphtho[2,1-a]azulen-7-one 
• 1010103-64-6 2-[(E)-2-(3-morpholin-4-ylmethyl-phenyl)vinyl]-8,9,10,11-tetrahydro-3,8,11-triazabenzo[a]fluoren-7-one 
• 1010104-13-8 2-[(tert-butoxycarbonyl-methyl-amino)methyl]-8-((E)-styryl)-1H-pyrrolo[2,3-f]isoquinoline-3-carboxylic acid tert-butyl ester 
• 1010104-03-6 2-(tert-butoxycarbonylamino-methyl)-8-((E)-styryl)-1H-pyrrolo[2,3-f]isoquinoline-3-carboxylic acid tert-butyl ester 
• 1010104-05-8 2-tert-butyloxycarbonyl-aminooxymethyl-8-((E)-styryl)-1H-pyrrolo[2,3-f]isoquinoline-3-carboxylic acid tert-butyl ester 
• 1010103-54-4 2-(2-trifluoromethylphenyl)-9,10-dihydro-8H-3,8,10-triazapentaleno[2,1-a]naphthalen-7-one 
• 1010103-94-2 2-(3-fluoro-4-methoxyphenyl)-8,9,10,11-tetrahydro-3,8,11-triazabenzo[a]fluoren-7-one 
• 1010103-32-8 2-(4-fluorophenyl)-9,10,11,12-tetrahydro-8H-3,8,12-triaza-naphtho[2,1-a]azulen-7-one 
• 1010104-11-6 2-methoxymethyl-8-((E)-styryl)-1H-pyrrolo[2,3-f]isoquinoline-3-carboxylic acid tert-butyl ester 
• 1010103-39-5 2-(4-methoxyphenyl)-9,10,11,12-tetrahydro-8H-3,8,12-triaza-naphtho[2,1-a]azulen-7-one 
• 1010103-31-7 2-((E)-styryl)-9,10,11,12-tetrahydro-8H-3,8,12-triaza-naphtho[2,1-a]azulen-7-one 
• 1010103-40-8 2-methoxymethyl-8-((E)-styryl)-1H-pyrrolo[2,3-f]isoquinoline-3-carboxylic acid amide 
• 1010103-27-1 2-((E)-styryl)-10,11-dihydro-9-oxa-3,8,11-triaza-benzo[a]fluoren-7-one 

Relevant articles and documents

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

PYRROLO[2,3-C]PYRIDINES AS IMAGING AGENTS FOR NEUROFIBRILARY TANGLES

Pyrrolopyridine compounds of formula (I) or their pharmaceutically acceptable salts are disclosed, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha- synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, the compounds are used as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. Futher, the compounds are useful for measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.

TRPV1 ANTAGONISTS

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.